Expertise in
28
conditions

Dr. Andrei R. Shustov

Hematology Oncology | Oncology | Hematology
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
 (2132.5 mi)
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
 (2132.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Andrei Shustov is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Shustov is highly rated in 28 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shustov is currently accepting new patients.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in WA
Languages Spoken
English
German
Portuguese
Russian
Ukrainian
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Premera

Locations

825 Eastlake Avenue E, G3-200, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Other
Study Drugs: High Dose Chemotherapy, Autologous Stem Cell Transplant, Romidepsin
Study Phase: Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: October 10, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 7 Less Clinical Trials

97 Total Publications

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.
Journal: Blood advances
Published: January 10, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology
Expertise in
22
conditions
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 mi)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Shadman is highly rated in 22 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

Chaitra S. Ujjani
Expertise in
20
conditions
Dr. Chaitra S. Ujjani
Hematology Oncology | Hematology | Oncology
Expertise in
20
conditions
Dr. Chaitra S. Ujjani
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 mi)
206-288-1000
Languages Spoken:
English, Hindi, Nepali, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Chaitra Ujjani is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Ujjani is highly rated in 20 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Ujjani is currently accepting new patients.

Ryan D. Cassaday
Expertise in
17
conditions
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 mi)
206-598-4333
Languages Spoken:
English, Mandarin, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Cassaday is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Cassaday is highly rated in 17 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cassaday is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile